The Effects of Trends in Osteoporosis Treatment on the Incidence of Fractures

被引:4
作者
Horikawa, Akira [1 ]
Miyakoshi, Naohisa [2 ]
Hongo, Michio [2 ]
Kasukawa, Yuji [2 ]
Shimada, Yoichi [2 ]
Kodama, Hiroyuki [3 ]
Sano, Akihisa [1 ]
机构
[1] Shizuoka Tokusyukai Hosp, 1-11 Surugaku Simokawahara Minami, Shizuoka 4210117, Japan
[2] Akita Univ, Dept Orthoped Surg, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan
[3] South Akita Orthoped Clin, 96-2 Kaidousita, Syowa Ookubo, Katagami 0181401, Japan
关键词
POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; RISK; BISPHOSPHONATES; EFFICACY; PREVENTION; DENOSUMAB; TRIAL; TERIPARATIDE; IBANDRONATE;
D O I
10.1155/2021/5517247
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
We analyzed the data about the preferences of medication and incidence of fractures between osteoporosis patients from 2012 to 2016. Our results suggested that the number of patients treated with intravenous and subcutaneous injections increased and the incidence of fracture was lower in intravenous and subcutaneous injections than oral medications. Objective. This study focused on the trends in antiosteoporosis drug preferences and compared the incidence of fractures between patients treated orally and those who were exposed to an awareness campaign and assigned to intravenous/subcutaneous treatment. Methods. Our hospital registry included 1,716 osteoporotic women who were over 65 years of age without preexisting vertebral and nonvertebral fractures over 1 year before this study, with bone mineral density (BMD) < -2.5 standard deviation (SD) and fracture assessment tool (FRAX) score > 20%, who were given 1,337 oral and 379 intravenous/subcutaneous prescriptions to treat their osteoporosis. Self-administered surveys (2012, 2013, 2014, 2015, and 2016) collected data on trends of preferences among nine drugs and fracture prevention using relative risk reduction (RRR). Results. The number of patients taking oral prescriptions decreased gradually from 2012 to 2016, while the number of patients treated with intravenous and subcutaneous injections increased. The incidence of fracture was lower in patients receiving intravenous and subcutaneous injections than in patients taking oral medications. Conclusion. These findings indicate a decrease in oral prescriptions for osteoporosis treatment and that treatment for osteoporosis using intravenous or subcutaneous injections of antiosteoporosis drugs is more effective for preventing fractures.
引用
收藏
页数:7
相关论文
共 32 条
[1]   Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].
Adler, Robert A. ;
El-Hajj Fuleihan, Ghada ;
Bauer, Douglas C. ;
Camacho, Pauline M. ;
Clarke, Bart L. ;
Clines, Gregory A. ;
Compston, Juliet E. ;
Drake, Matthew T. ;
Edwards, Beatrice J. ;
Favus, Murray J. ;
Greenspan, Susan L. ;
McKinney, Ross, Jr. ;
Pignolo, Robert J. ;
Sellmeyer, Deborah E. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (01) :16-35
[2]   Concern and Risk Perception: Effects on Osteoprotective Behaviour [J].
Barcenilla-Wong, A. L. ;
Chen, J. S. ;
March, L. M. .
JOURNAL OF OSTEOPOROSIS, 2014, 2014
[3]   Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up [J].
Belhassen, M. ;
Confavreux, C. B. ;
Cortet, B. ;
Lamezec, L. ;
Ginoux, M. ;
Van Ganse, E. .
OSTEOPOROSIS INTERNATIONAL, 2017, 28 (03) :853-862
[4]  
Black D.M., 2001, NEW ENGL J MED, V344, P1434
[5]   The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) [J].
Black, Dennis M. ;
Reid, Ian R. ;
Boonen, Steven ;
Bucci-Rechtweg, Christina ;
Cauley, Jane A. ;
Cosman, Felicia ;
Cummings, Steven R. ;
Hue, Trisha F. ;
Lippuner, Kurt ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Martinez, Ruvie Lou Maria ;
Tan, Monique ;
Ruzycky, Mary Ellen ;
Su, Guoqin ;
Eastell, Richard .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (02) :243-254
[6]  
Carolyn J.C., 2014, ANN INTERN MED, V161, P711
[7]   Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis [J].
Chen, Ling-Xiao ;
Zhou, Zhi-Rui ;
Li, Yu-Lin ;
Ning, Guang-Zhi ;
Zhang, Tian-Song ;
Zhang, Di ;
Feng, Shi-Qing .
PLOS ONE, 2015, 10 (05)
[8]   Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249
[9]   Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
San Martin, Javier ;
McClung, Michael R. ;
Siris, Ethel S. ;
Eastell, Richard ;
Reid, Ian R. ;
Delmas, Pierre ;
Zoog, Holly B. ;
Austin, Matt ;
Wang, Andrea ;
Kutilek, Stepan ;
Adami, Silvano ;
Zanchetta, Jose ;
Libanati, Cesar ;
Siddhanti, Suresh ;
Christiansen, Claus .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :756-765
[10]   Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis [J].
Dhillon, Sohita .
DRUGS, 2016, 76 (17) :1683-1697